Provided by Tiger Trade Technology Pte. Ltd.

Palvella Therapeutics

152.95
+2.401.59%
Volume:125.22K
Turnover:19.10M
Market Cap:2.20B
PE:-31.23
High:157.00
Open:153.76
Low:149.68
Close:150.55
52wk High:161.38
52wk Low:51.38
Shares:14.41M
Float Shares:8.40M
Volume Ratio:0.64
T/O Rate:1.49%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-4.8978
EPS(LYR):-3.7076
ROE:-46.63%
ROA:-22.05%
PB:10.16
PE(LYR):-41.25

Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Mar 30

Palvella Therapeutics announces Phase 2 DSAP trial start in H2 2026; Phase 3 SELVA study meets primary endpoint on mLM-IGA (p<0.001)

Reuters
·
Mar 27

Palvella Therapeutics Highlights Continued Progress Across Rare Skin Disease Pipeline with Two Poster Presentations at the 2026 American Academy of Dermatology Annual Meeting

GlobeNewswire
·
Mar 27

Has Palvella Therapeutics (PVLA) Run Too Far After Its 334% One-Year Surge?

Simply Wall St.
·
Mar 26

Palvella Therapeutics Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Mar 24

Analysts Offer Insights on Healthcare Companies: Palvella Therapeutics (PVLA) and Neurogene (NGNE)

TIPRANKS
·
Mar 24

Palvella Therapeutics Inc. : H.c. Wainwright Raises Target Price to $270 From $255

THOMSON REUTERS
·
Mar 24

Palvella Therapeutics to host full-year 2025 financial results conference call and corporate update

Reuters
·
Mar 24

Palvella Therapeutics appoints Jennifer J. McDonough as SVP of Market Access and Patient Services

Reuters
·
Mar 23

Palvella Therapeutics (PVLA) Receives a Rating Update from a Top Analyst

TIPRANKS
·
Mar 21

Analysts Offer Insights on Healthcare Companies: Spectral AI (MDAI) and Palvella Therapeutics (PVLA)

TIPRANKS
·
Mar 19

Palvella Therapeutics Is Maintained at Buy by Chardan Capital

Dow Jones
·
Mar 17

Palvella Therapeutics Secures European Patent No. 3565520 for QTORIN Rapamycin Anhydrous Gel

Reuters
·
Mar 16

Palvella Therapeutics launches ‘BEYOND mLM’ disease awareness campaign

TIPRANKS
·
Mar 10

Palvella Therapeutics Launches "BEYOND mLM" Disease Awareness Campaign for Microcystic Lymphatic Malformations in Collaboration with Leading Lymphatic, Vascular, and Dermatology Nonprofit Organizations

GlobeNewswire
·
Mar 10